Trodelvy Trodelvy

TRODELVY(sacituzumab govitecan-hziy)

Company: Immunomedics

Approval Status: Approved on 4/22/2020

Specific treatment: Metastatic triple-negative breast cancer

Mechanism of Action:

Sacituzumab govitecan-hziy is a Trop-2-directed antibody-drug conjugate. Sacituzumab is a humanized antibody that recognizes Trop-2. The small molecule, SN-38, is a topoisomerase I inhibitor, which is covalently attached to the antibody by a linker. Pharmacology data suggest that sacituzumab govitecan-hziy binds to Trop-2-expressing cancer cells and is internalized with the subsequent release of SN-38 via hydrolysis of the linker. SN-38 interacts with topoisomerase I and prevents re-ligation of topoisomerase I-induced single strand breaks. The resulting DNA damage leads to apoptosis and cell death. Sacituzumab govitecan-hziy decreased tumor growth in mouse xenograft models of triple-negative breast cancer.

Dosage form/Route:

For injection: 180 mg lyophilized powder in single-dose vials for reconstitution.

Side effects:

Most common adverse reactions (incidence >25%) in patients with mTNBC are nausea, neutropenia, diarrhea, fatigue, anemia, vomiting, alopecia, constipation, rash, decreased appetite, and abdominal pain.